New Drugs and Clinical Research · us
From Long-Term Suppression to Control After Treatment Ends: FDA Approves First Antisense Therapy for Hepatitis B
Hibsago offers some patients with chronic hepatitis B a chance to maintain viral control after stopping treatment, but about one in five achieved this goal in trials. Strict eligibility criteria and warnings about liver and platelet safety also set clear boundaries for the new therapy.
For many patients with chronic hepatitis B, medication can suppress the virus, but treatment may continue for years. On October 20, the U.S. Food and Drug Administration (FDA) announced its approval of GSK’s Hibsago (bepirovirsen), offering some patients the possibility of controlling the infection after stopping treatment. It is the first antisense oligonucleotide drug approved in the United States to treat chronic hepatitis B; its advance lies in making a finite course of treatment an attainable treatment goal.
The approval has clear eligibility requirements: it applies to adults without cirrhosis who have received at least six months of nucleos(t)ide analogue treatment and whose blood HBV DNA is suppressed. Their hepatitis B surface antigen (HBsAg) level must also be no higher than 3,000 IU/mL, as confirmed by an FDA-authorized test. The FDA also authorized Roche’s Elecsys HBsAg II quant II RxDx companion diagnostic test to help select patients and monitor treatment.
Bepirovirsen targets the RNA the virus needs to produce proteins and replicate, thereby reducing viral products, including surface antigen. However, an injection course lasting about six months does not mean that all medication can be stopped after six months. According to the FDA, patients must add up to 24 weeks of subcutaneous injections to their existing antiviral treatment and continue their original medication for at least 24 weeks after the final dose. Whether treatment can then be stopped is assessed based on clinical and laboratory criteria. GSK said patients may choose to self-inject after the first dose.
In the Phase 3 B-Well 1 and B-Well 2 trials supporting the approval, a total of 1,220 participants received bepirovirsen. Of these, 233, or about 19%, maintained viral control and had undetectable surface antigen 24 weeks after stopping all hepatitis B treatment; none of the 614 placebo recipients met this endpoint. Secondary endpoint results released by GSK showed that among participants whose baseline surface antigen level was no higher than 1,000 IU/mL, 26% met the endpoint (200 of 768), compared with none of the 393 placebo recipients.
This type of outcome is called a “functional cure,” but it cannot be taken to mean that the virus has been completely eliminated from the body or that the effect will last a lifetime. HCPLive also emphasized this distinction in its summary of the trial results. For readers, the 19% figure represents clinical evidence that control after stopping treatment, previously difficult to achieve, is possible. It also means that most participants who received the new drug did not achieve this endpoint; longer-term durability still requires follow-up.
Beyond efficacy, the safety burden is equally concrete. Hibsago carries a boxed warning for serious liver reactions and low platelet counts, the latter of which may increase the risk of life-threatening bleeding. Safety information released by GSK requires platelet monitoring at least weekly during treatment and permanent discontinuation if the platelet count falls below 50 × 10⁹/L. A pooled analysis cited by HCPLive showed serious adverse event rates of 7% in the new drug group and 4% in the placebo group. This comparison does not mean that all events were caused by the drug, but it underscores the need for close monitoring during treatment.
Next, practical access to the therapy will also influence the changes this approval brings. According to Reuters, Hibsago has been approved in Japan and is under regulatory review in China and Europe; as of the report’s publication, GSK had not provided Reuters with U.S. pricing or a supply timeline. Moving from approval into clinical practice will require, alongside the drug itself, quantitative testing, regular blood tests and follow-up after treatment ends to turn the opportunity to stop treatment demonstrated in trials into part of routine care.